Nasopharyngeal cancer: Molecular landscape

Journal of Clinical Oncology

Volumn 33, Issue 29, 2015, Pages 3346-3355

  Bruce, Jeff P ^a   Yip, Kenneth ^a   Bratman, Scott V ^a,b   Ito, Emma ^a,b   Liu, Fei Fei ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPSTEIN BARR VIRUS ANTIGEN 1; MICRORNA; PROTEIN LMP1; PROTEIN LMP2A; PROTEIN LMP2B; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA;

ANTIGEN RECOGNITION; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COPY NUMBER VARIATION; DNA METHYLATION; EPIGENETICS; EPSTEIN BARR VIRUS; GENE DELETION; GENE INSERTION; GENE TRANSLOCATION; HISTONE MODIFICATION; HUMAN; IMMUNE RESPONSE; MOLECULAR INTERACTION; NASOPHARYNX CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; NASOPHARYNX TUMOR; RISK FACTOR; VIROLOGY;

CELL PROLIFERATION; DNA METHYLATION; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; RISK FACTORS; RNA, VIRAL;

EID: 84944193218     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.7846     Document Type: Review

References (117)

1. Lo KW, Chung GT, To KF: Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol 22: 79-86, 2012
2. Maxwell JH, Kumar B, Feng FY, et al: HPVpositive/ p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 32: 562-567, 2010
3. Stenmark MH, McHugh JB, Schipper M, et al: Nonendemic HPV-positive nasopharyngeal carcinoma: Association with poor prognosis. Int J Radiat Oncol Biol Phys 88: 580-588, 2014
4. Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777, 2006
5. Xue WQ, Qin HD, Ruan HL, et al: Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: A comprehensive metaanalysis of studies conducted between 1979 and 2011. Am J Epidemiol 178: 325-338, 2013
6. Chan AS, To KF, Lo KW, et al: High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 60: 5365-5370, 2000
7. Chan AS, To KF, Lo KW, et al: Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int J Cancer 102: 300-303, 2002
8. Frappier L: Role of EBNA1 in NPC tumourigenesis. Semin Cancer Biol 22: 154-161, 2012
9. Dawson CW, Port RJ, Young LS: The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 22: 144-153, 2012
10. Dawson CW, Rickinson AB, Young LS: Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344: 777-780, 1990
11. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011
12. Ohtani N, Brennan P, Gaubatz S, et al: Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. J Cell Biol 162: 173-183, 2003
13. Zhao Y, Wang Y, Zeng S, et al: LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: Evidence from a metaanalysis. J Clin Pathol 65: 41-45, 2012
14. Ayadi W, Karray-Hakim H, Khabir A, et al: Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res 28: 2161-2167, 2008
15. Brooks L, Yao QY, Rickinson AB, et al: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66: 2689-2697, 1992
16. Kong QL, Hu LJ, Cao JY, et al: Epstein- Barr virus-encoded LMP2A induces an epithelialmesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 6: E1000940, 2010
17. Longnecker R: Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 79: 175-200, 2000
18. Allen MD, Young LS, Dawson CW: The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 79: 1789-1802, 2005
19. Shah KM, Stewart SE, Wei W, et al: The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene 28: 3903-3914, 2009
20. Gruhne B, Sompallae R, Marescotti D, et al: The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci U S A 106: 2313-2318, 2009
21. Gottifredi V, Prives C: P53 and PML: New partners in tumor suppression. Trends Cell Biol 11: 184-187, 2001
22. Takada K: Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Semin Cancer Biol 22: 162-165, 2012
23. Pfeffer S, Zavolan M, Grasser FA, et al: Identification of virus-encoded microRNAs. Science 304: 734-736, 2004
24. Cosmopoulos K, Pegtel M, Hawkins J, et al: Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 83: 2357-2367, 2009
25. Lo AK, To KF, Lo KW, et al: Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A 104: 16164-16169, 2007
26. Lung RW, Tong JH, Sung YM, et al: Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 11: 1174-1184, 2009
27. Choy EY, Siu KL, Kok KH, et al: An Epstein- Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 205: 2551-2560, 2008
28. Marquitz AR, Mathur A, Nam CS, et al: The Epstein-Barr virus BART microRNAs target the proapoptotic protein Bim. Virology 412: 392-400, 2011
29. Dolken L, Malterer G, Erhard F, et al: Systematic analysis of viral and cellular microRNA targets in cells latently infected with human gamma-herpesviruses by RISC immunoprecipitation assay. Cell Host Microbe 7: 324-334, 2010
30. Nachmani D, Stern-Ginossar N, Sarid R, et al: Diverse herpesvirus microRNAs target the stressinduced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5: 376-385, 2009
31. Iizasa H, Wulff BE, Alla NR, et al: Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 285: 33358-33370, 2010
32. Lin DC, Meng X, Hazawa M, et al: The genomic landscape of nasopharyngeal carcinoma. Nat Genet 46: 866-871, 2014
33. Lo KW, Cheung ST, Leung SF, et al: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56: 2721-2725, 1996
34. Kwong J, Lo KW, To KF, et al: Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8: 131-137, 2002
35. Spruck CH 3rd, Tsai YC, Huang DP, et al: Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 52: 4787-4790, 1992
36. Sun Y, Hegamyer G, Cheng YJ, et al: An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 89: 6516-6520, 1992
37. Effert P, McCoy R, Abdel-Hamid M, et al: Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 66: 3768-3775, 1992
38. Lo KW, Kwong J, Hui AB, et al: High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61: 3877-3881, 2001
39. Lo K, Tsao S, Leung S, et al: Detailed deletion mapping on the short arm of chromosome-3 in nasopharyngeal carcinomas. Int J Oncol 4: 1359-1364, 1994
40. Hui AB, Lo KW, Leung SF, et al: Loss of heterozygosity on the long arm of chromosome 11 in nasopharyngeal carcinoma. Cancer Res 56: 3225-3229, 1996
41. Lung HL, Bangarusamy DK, Xie D, et al: THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 24: 6525-6532, 2005
42. Hui AB, Lo KW, Kwong J, et al: Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog 38: 170-178, 2003
43. Lung HL, Cheung AK, Xie D, et al: TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res 66: 9385-9392, 2006
44. Seng TJ, Low JS, Li H, et al: The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 26: 934-944, 2007
45. Guan Z, Zhang J, Wang J, et al: SOX1 down-regulates beta-catenin and reverses malignant phenotype in nasopharyngeal carcinoma. Mol Cancer 13: 257, 2014
46. Li HP, Huang HY, Lai YR, et al: Silencing of miRNA-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. Oncotarget 5: 7610-7624, 2014
47. Tong JH, Ng DC, Chau SL, et al: Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 10: 253, 2010
48. Lo KW, Teo PM, Hui AB, et al: High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 60: 3348-3353, 2000
49. Hui AB, Or YY, Takano H, et al: Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 65: 8125-8133, 2005
50. Hui AB, Lo KW, Leung SF, et al: Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 82: 498-503, 1999
51. Or YY, Hui AB, To KF, et al: PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer 118: 1065-1067, 2006
52. Jiang N, Liu N, Yang F, et al: Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma. Oncol Rep 32: 1661-1669, 2014
53. Zhang ZC, Fu S, Wang F, et al: Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther 7: 457-467, 2014
54. Or YY, Chung GT, To KF, et al: Identification of a novel 12p13.3 amplicon in nasopharyngeal carcinoma. J Pathol 220: 97-107, 2010
55. Huang DP, Lo KW, van Hasselt CA, et al: A region of homozygous deletion on chromosome 9p21-22 in primary nasopharyngeal carcinoma. Cancer Res 54: 4003-4006, 1994
56. Wang GL, Lo KW, Tsang KS, et al: Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 81: 1122-1126, 1999
57. Li HM, Man C, Jin Y, et al: Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer 119: 1567-1576, 2006
58. Dammann R, Li C, Yoon JH, et al: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000
59. Fernandes MS, Carneiro F, Oliveira C, et al: Colorectal cancer and RASSF family: A special emphasis on RASSF1A. Int J Cancer 132: 251-258, 2013
60. Chow LS, Lam CW, Chan SY, et al: Identification of RASSF1A modulated genes in nasopharyngeal carcinoma. Oncogene 25: 310-316, 2006
61. Song SJ, Song MS, Kim SJ, et al: Aurora A regulates prometaphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity. Cancer Res 69: 2314-2323, 2009
62. Man C, Rosa J, Lee LT, et al: Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells. Oncogene 26: 3069-3080, 2007
63. Morrison JA, Gulley ML, Pathmanathan R, et al: Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res 64: 5251-5260, 2004
64. Chung GT, Lung RW, Hui AB, et al: Identification of a recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated nasopharyngeal carcinoma. J Pathol 231: 158-167, 2013
65. Valouev A, Weng Z, Sweeney RT, et al: Discovery of recurrent structural variants in nasopharyngeal carcinoma. Genome Res 24: 300-309, 2014
66. Cancer Genome Atlas Network: Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576-582, 2015
67. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202-209, 2014
68. Chung GT, Lou WP, Chow C, et al: Constitutive activation of distinct NF-kB signals in EBVassociated nasopharyngeal carcinoma. J Pathol 231: 311-322, 2013
69. Chou CC, Chou MJ, Tzen CY: PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol 26: 322-326, 2009
70. Chan SL, Cui Y, van Hasselt A, et al: The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest 87: 644-650, 2007
71. Alajez NM, Lenarduzzi M, Ito E, et al: MiR- 218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2- ROBO1 pathway. Cancer Res 71: 2381-2391, 2011
72. Tong ZT, Cai MY, Wang XG, et al: EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31: 583-594, 2012
73. Alajez NM, Shi W, Hui AB, et al: Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis 1: E85, 2010
74. Yan M, Zhang Y, He B, et al: IKKa restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat Commun 5: 3661, 2014
75. Minarovits J: Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 310: 61-80, 2006
76. Matsushita H, Vesely MD, Koboldt DC, et al: Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482: 400-404, 2012
77. Li J, Zeng XH, Mo HY, et al: Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: Implications for tumor immunotherapy. PLoS One 2: E1122, 2007
78. Hutajulu SH, Kurnianda J, Tan IB, et al: Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma. Ther Clin Risk Manag 10: 721-736, 2014
79. Vicari AP, Trinchieri G: Interleukin-10 in viral diseases and cancer: Exiting the labyrinth? Immunol Rev 202: 223-236, 2004
80. Levitskaya J, Sharipo A, Leonchiks A, et al: Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 94: 12616-12621, 1997
81. Mrizak D, Martin N, Barjon C, et al: Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J Natl Cancer Inst 107: 363, 2014
82. Hildesheim A, Wang CP: Genetic predisposition factors and nasopharyngeal carcinoma risk: A review of epidemiological association studies, 2000- 2011-Rosetta Stone for NPC: Genetics, viral infection, and other environmental factors. Semin Cancer Biol 22: 107-116, 2012
83. Martorelli D, Houali K, Caggiari L, et al: Spontaneous T cell responses to Epstein-Barr virusencoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. Int J Cancer 123: 1100-1107, 2008
84. Hsu WL, Tse KP, Liang S, et al: Evaluation of human leukocyte antigen-A (HLA-A), other non-HLA markers on chromosome 6p21 and risk of nasopharyngeal carcinoma. PLoS One 7: E42767, 2012
85. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012
86. Yip KW, Shi W, Pintilie M, et al: Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 12: 5726-5732, 2006
87. Qian CN, Guo X, Cao B, et al: Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62: 589-596, 2002
88. Huang C, Tang H, Zhang W, et al: Integrated analysis of multiple gene expression profiling datasets revealed novel gene signatures and molecular markers in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 21: 166-175, 2012
89. Tulalamba W, Larbcharoensub N, Janvilisri T: ERBB3 as an independent prognostic marker for nasopharyngeal carcinoma. J Clin Pathol 67: 667-672, 2014
90. Hui AB, Bruce JP, Alajez NM, et al: Significance of dysregulated metadherin and microRNA- 375 in head and neck cancer. Clin Cancer Res 17: 7539-7550, 2011
91. Li J, Wen Q, Xu L, et al: Fatty acid synthaseassociated protein with death domain: A prognostic factor for survival in patients with nasopharyngeal carcinoma. Hum Pathol 45: 2447-2452, 2014
92. Liu N, Chen NY, Cui RX, et al: Prognostic value of a microRNA signature in nasopharyngeal carcinoma: A microRNA expression analysis. Lancet Oncol 13: 633-641, 2012
93. Bruce JP, Hui AB, Shi W, et al: Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. Oncotarget 6: 4537-4550, 2015
94. Li J, Mo HY, Xiong G, et al: Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumorinfiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem 287: 35484-35495, 2012
95. Li M, Li C, Li D, et al: Periostin, a stromaassociated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma. Clin Exp Metastasis 29: 865-877, 2012
96. Diaz LA Jr, Bardelli A: Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 32: 579-586, 2014
97. Lo YM, Chan LY, Lo KW, et al: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59: 1188-1191, 1999
98. Chan KC, Zhang J, Chan AT, et al: Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63: 2028-2032, 2003
99. Lo YM, Chan LY, Chan AT, et al: Quantitative and temporal correlation between circulating cellfree Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 59: 5452-5455, 1999
100. To EW, Chan KC, Leung SF, et al: Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 9: 3254-3259, 2003
101. Lin JC, Wang WY, Chen KY, et al: Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350: 2461-2470, 2004
102. Hsu CL, Chang KP, Lin CY, et al: Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head Neck 34: 1064-1070, 2012
103. Lin JC, Chen KY, Wang WY, et al: Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: Relationship to distant metastasis and survival. J Clin Oncol 19: 2607-2615, 2001
104. Chan KC, Hung EC, Woo JK, et al: Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer 119: 1838-1844, 2013
105. Wang WY, Twu CW, Lin WY, et al: Plasma Epstein-Barr virus DNA screening followed by (1)(8)F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma. Cancer 117: 4452-4459, 2011
106. Twu CW, Wang WY, Chen CC, et al: Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys 89: 21-29, 2014
107. Le QT, Zhang Q, Cao H, et al: An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarkerguided trials in nasopharyngeal carcinoma. Clin Cancer Res 19: 2208-2215, 2013
108. Lennette ET, Winberg G, Yadav M, et al: Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer 31A: 1875-1878, 1995
109. Leung SF, Tam JS, Chan AT, et al: Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 50: 339-345, 2004
110. Yu KJ, Hsu WL, Pfeiffer RM, et al: Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res 17: 1906-1914, 2011
111. Twu CW, Wang WY, Liang WM, et al: Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 67: 130-137, 2007
112. Houali K, Wang X, Shimizu Y, et al: A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin Cancer Res 13: 4993-5000, 2007
113. Zhang G, Zong J, Lin S, et al: Circulating Epstein-Barr virus microRNAs miR-BART7 and miRBART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment. Int J Cancer 136: E301-E312, 2015
114. Lo KW, Lo YM, Leung SF, et al: Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem 45: 1292-1294, 1999
115. Wang HY, Yan LX, Shao Q, et al: Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing. Clin Chem 60: 773-782, 2014
116. Wong TS, Kwong DL, Sham JS, et al: Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 10: 2401-2406, 2004
117. Xu J, Menezes J, Prasad U, et al: Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer 84: 396-399, 1999